SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the maximum tolerated dose (MTD) of SAR3419 according
to the dose limiting toxicities (DLTs) observed when administered as a single agent once
weekly.
Secondary objectives are:
- to characterize the global safety profile
- to evaluate the pharmacokinetic (PK) profile of SAR3419 in the proposed dosing schedule
- to assess preliminary evidence of anti-lymphoma activity.